In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.
Featured articles:
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode we’ll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.
Featured articles:
11,147 Listeners
140 Listeners
318 Listeners
499 Listeners
75 Listeners
26 Listeners
1,157 Listeners
2 Listeners
363 Listeners
373 Listeners
1 Listeners
48 Listeners
190 Listeners
30 Listeners
4 Listeners